Search bioRxiv⌕ Search

Biology subjects

Nixon, J.

Publications and source records attributed to Nixon, J..

2 recordsLinked to original sources

Computational analysis of therapeutic potential for simplified Piper. spp- derived medicinal mixtures in anxiety, sleep, pain and seizure.

Phytomedicines have played a vital role in traditional medical systems globally, particularly in providing culturally relevant and accessible healthcare solutions. Piper methysticum, known as Kava, is a traditional Pacific Island phytomedicine with clinically validated anxiolytic properties, primarily attributed to its Kavalactones. However, the biogeographically restricted distribution of Piper methysticum and the ecological and cultural concerns surrounding its widespread adoption highlight the need to explore alternative sources within the Piper genus. This study investigates whether other species within the Piper genus, used phytomedically in non-Pacific contexts, exhibit similar therapeutic efficacy for anxiety, stress, and related disorders including Post-Traumatic Stress Disorder (PTSD). We employed a computational approach utilizing a novel data platform of non-Western phytomedical pharmacopeias to analyze the secondary metabolomes of various Piper species. Network analysis and multidimensional data projections were used to compare the chemical composition and therapeutic indications of these species with those of Piper methysticum. Our findings suggest that while Kavalactones are predominantly unique to Piper methysticum, other Piper species also contain bioactive compounds associated with anxiolytic and stress-relieving effects. These results provide insight into the potential for culturally and biogeographically contextualized approaches to PTSD treatment, beyond the exclusive use of Kava, and lay the groundwork for future research into alternative phytomedicinal therapies within the Piper genus.

pharmacology and toxicology↗

Microbiome-induced Increases and Decreases in Bone Tissue Strength can be Initiated After Skeletal Maturity

Recent studies in mice have indicated that the gut microbiome can regulate bone tissue strength. However, prior work involved modifications to the gut microbiome in growing animals and it is unclear if the same changes in the microbiome, applied later in life, would change matrix strength. Here we changed the composition of the gut microbiome before and/or after skeletal maturity (16 weeks of age) using oral antibiotics (ampicillin + neomycin). Male and female mice (n=143 total, n=12-17/group/sex) were allocated into five study groups:1) Unaltered, 2) Continuous (dosing 4-24 weeks of age), 3) Delayed (dosing only 16-24 weeks of age), 4) Initial (dosing 4-16 weeks of age, suspended at 16 weeks), and 5) Reconstituted (dosing from 4-16 weeks following by fecal microbiota transplant from Unaltered donors). Animals were euthanized at 24 weeks of age. In males, bone matrix strength in the femur was 25-35% less than expected from geometry in mice from the Continuous (p= 0.001), Delayed (p= 0.005), and Initial (p=0.040) groups as compared to Unaltered. Reconstitution of the gut microbiota, however, led to a bone matrix strength similar to Unaltered animals (p=0.929). In females, microbiome-induced changes in bone matrix strength followed the same trend as males but were not significantly different, demonstrating sex-related differences in the response of bone matrix to the gut microbiota. Minor differences in chemical composition of bone matrix were observed (Raman spectroscopy). Our findings indicate that microbiome-induced impairment of bone matrix in males can be initiated and/or reversed after skeletal maturity. The portion of the femoral cortical bone formed after skeletal maturity (16 weeks) is small; however, this suggests that microbiome-induced changes in bone matrix occur without osteoblast/osteoclast turnover using an, as of yet unidentified mechanism. These findings add to evidence that the mechanical properties of bone matrix can be altered in the adult skeleton.

bioengineering↗